NightstaRx Ltd. (Nightstar) of Boston and London said on June 29 that it closed a $45m Series C round backed by new investors Wellington Management Co. and Redmile Group along with prior funders Syncona and New Enterprise Associates (NEA). The gene therapy company, which previously raised a $35m Series B round in late 2015, will use its cash on multiple studies: a planned Phase III clinical trial for lead product candidate NSR-REP1 in choroideremia, an inherited X-linked recessive disease that leads to blindness; an ongoing Phase I/II trial of NSR-RPGR for X-linked retinitis pigmentosa, and a future Phase I/II study of an unnamed gene therapy for an inherited form of macular dystrophy. (Also see "NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease" - Scrip, 12 November, 2015.)

Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund

More from Financing

More from Business